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ABSTRACT 
Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess 
the role of anti-neuronal autoantibodies (NAAs) as biomarkers of treatment outcome, we 
assessed NAAs in serial samples from SCLC patients treated with chemoimmunotherapy 
compared to chemotherapy alone. We evaluated 2 cohorts: in cohort 1 (C1), 47 patients 
received standard platinum/etoposide, and in cohort 2 (C2), 38 patients received ipilimumab, 
carboplatin and etoposide. Serum samples at baseline and subsequent time points were 
analyzed for the presence of NAAs. NAAs were detected at baseline in 25 patients (53.2%) in 
C1 and in 20 patients (52.6%) in C2 (most frequently anti-Sox1). NAA at baseline was 
associated with limited disease (75% vs 50%; p: 0.096) and better overall survival (15.1m vs 
11.7m; p: 0.032) in C1. Thirteen patients (28.9%) showed 2 or more reactivities before 
treatment; this was associated with worse PFS (5.5m vs 7.3m; p: 0.005) in patients treated 
with chemoimmunotherapy. NAA titers decreased after therapy in 68.9% patients, with no 
differential patterns of change between cohorts. Patients whose NAA titer decreased after 
treatment, showed longer OS [18.5m (95% CI: 15.8 ± 21.2)] compared with those whose 
NAA increased [12.3m (95% CI: 8.1 ± 16.5; p 0.049)], suggesting that antibody levels 
correlate to tumor load. Our findings reinforce the role of NAAs as prognostic markers and 
tumor activity/burden in SCLC, warrant further investigation in their predictive role for 
immunotherapy and raise concern over the use of immunotherapy in patients with more than 
one anti-NAA reactivity. 
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INTRODUCTION 
Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer1,2. 
Although robust and often dramatic clinical responses are achieved with platinum-based first-
line treatment, recurrence/progression usually occurs early and is resistant to available 
treatments3. Outcomes in patients with stage IV disease remain poor with a median overall 
survival that rarely exceeds one year 1,4.   
Immunotherapy has led to a paradigm-shift in the treatment of solid tumors5,6. SCLC seems a 
particularly attractive target for immunotherapy. Paraneoplastic neurological syndromes 
(PNSs) are common in SCLC and are characterized by anti-cancer immune responses, which 
become clinically visible by off-tumor immune consequences against neuronal antigens, 
ectopically expressed by cancer cells and physiologically by the normal nervous system7. The 
better cancer specific survival outcomes in patients with autoimmune disease points to a 
protective effect, linked to these cross-reactive immune responses8,9. Moreover, high 
mutational load has been linked to benefit from immunotherapy 10 and SCLC falls into this 
category 2,11,12, most likely as a result of the tight association with tobacco smoking. 
Therefore, harnessing the immune system to fight SCLC seems a potentially promising 
strategy, although the best approach is currently uncertain.  
Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that blocks CTLA-413, 
and has been tested in SCLC. A phase II trial 14, showed a trend to improved overall survival 
with phased ipilimumab added to a platinum doublet. However, the confirmatory phase III 
trial 15 comparing ipilimumab and chemotherapy vs chemotherapy did not confirm better 
overall survival after chemoimmunotherapy. More recently, anti-PD-1 agents have also been 
tested in SCLC. Nivolumab (alone and in combination with ipilimumab) showed antitumor 
activity in SCLC patients with relapsed disease16. In a phase I trial, Pembrolizumab use led to 
objective responses greater than 30% of patients17.  
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Nonetheless, the majority of patients with SCLC do not benefit from checkpoint inhibitors 
and the absence of predictive biomarkers for patient selection may have contributed to 
negative trial results15. Additionally, clinically relevant autoimmune toxicity has been 
reported, including severe neurological PNS14,16,18 increasing the level of caution that is 
needed when investigating immunotherapy in SCLC. PD-L1 immunohistochemical 
expression, which is predictive for benefit from modulation of PD1/PDL1 in Non-Small Cell 
Lung cancer, does not appear to correlate with outcome in SCLC16,17. A confounding effect 
for the evaluation of PD-L1 status in the tumor is limited access to tissue due to small biopsy 
material or cytology diagnostic specimens, a well-recognized problem in SCLC19. Therefore, 
the need to develop predictive biomarkers remains an urgent priority in SCLC.  
With the aim of identifying potential biomarkers, we previously performed an exploratory 
analysis of the phase II ICE trial with a single cohort of patients treated with chemotherapy 
and ipilimumab. In this single arm study, positivity of autoantibodies at baseline was 
associated with improved outcomes18.  
In the current study we added a µcontrol¶ cohort treated with standard chemotherapy in order 
to assess the predictive vs. prognostic role of the neuronal autoantibodies. We also analyzed 
changes in autoantibody detection during treatment to evaluate the potential utility of serial 
sampling. 
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RESULTS 
3DWLHQWV¶FKDUDFWHULVWLFVDQGRXWFRPHV 
We included 85 SCLC patients: 47 treated with standard chemotherapy (cohort 1 herein) and 
38 with standard chemotherapy plus ipilimumab (cohort 2 herein3DWLHQWV¶FKDUDFWHULVWLFVDUH
shown in Table 1. The main differences between both cohorts were that cohort 1 (C1) 
included more men (74.5% vs 65.8%), 25% patients had limited stage and 15% patients 
presented with performance status (PS) 2 versus none in cohort 2. None of the patients had 
any neurological symptoms at diagnosis.  
Objective response rate (ORR) was 93.6% in C1 and 81.6% in C2. Median progression free 
survival (PFS) was 6.8 months (m) (95% CI: 6.1-7.6) in C1 and 6.9m (95% CI: 6.3-7.6) in C2 
(p=0.847). Overall survival (OS) was 13.3m (95% CI: 10.1-16.5) in C1 vs 17 m (95% CI: 4.5-
29.5) in C2 (p=0.987). When we selected patients with stage IV in C1, OS was 11.7m (95% 
CI: 7.6 ± 15.7). 
We assessed the impact of clinical variables on survival. Table 2 illustrates the association 
between clinical variables and OS combining both cohorts. PS:0 vs. PS>0 (p=0.019), limited 
stage (p=0.003) and response to first line chemotherapy (p<0.001) were associated with a 
significantly improved survival (Table 2).  
 
Neuronal autoantibody detection 
Neuronal autoantibodies (NAA) were detected at baseline in 25 patients (53.2%) in C1 and in 
20 patients (52.6%) in C2. In both cohorts, the most prevalent autoantibody was anti-Sox1 
(38.3% in C1 and 34.2% in C2), followed by anti-HuD and anti-Yo (Table 3, Figure 1 - left). 
Globally, 13 patients out of the 45 with baseline NAA (28.9%) showed 2 or more reactivities 
at any time-point (Supplementary Table 1); of these, 11 patients (24.5%), had 2 or more types 
of autoantibody at baseline. Eight patients (17.8%) in C1 showed 2 or more reactivities; one 
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of these patients was positive at baseline for anti-Sox1, but became also positive for anti-Yo 
after 3 cycles of chemotherapy. Five patients (11.1%) in C2 showed 2 or more reactivities; 
one of these patients was positive at baseline for anti-Yo, and became also positive for anti-
Gad65 after 8 weeks of treatment. Anti-Yo and Anti-Sox1 detection were associated with 
another NAA in 7/12 patients (58.3%) and 9/32 patients (28.1%), respectively. One patient 
showed reactivity for 4 NAA: anti-Sox1, anti-amphiphysin, anti-Ri and anti-HuD. In Figure 1 
(right) we illustrate the different multi-reactivities of NAA in patients of both cohorts.  
 
Association between neuronal autoantibodies and clinical characteristics and outcomes 
We next evaluated the association of the detection of NAA with clinical variables. Of 12 
patients with limited stage, 9 patients (75%) had detectable NAAs at baseline versus 36/72 
(50%) of patients with stage IV disease (p=0.096). This trend was also observed for anti-Sox1 
where 7/12 (58.3%) of patients with limited stage had detectable anti-Sox1 at baseline 
compared to 24/72 (33.3%) patients with stage IV (p=0.092). The presence of anti-HuD and 
anti-Yo did not show any correlation with stage. There was no association between sex, age 
or PS and detection of neither any baseline NAA nor specific autoantibodies. 
We assessed the association of NAAs with clinical outcomes. In patients with pre-treatment 
NAAs we observed a trend for better overall survival when both cohorts were analyzed 
together [14.8m (95% CI: 10.6-19) vs 12.1m (95% CI: 8.2-16); p: 0.089]. In patients treated 
with chemotherapy alone, this association was significant [15.1m (95% CI: 10.2-20) vs 11.7m 
(95%CI: 7.5-15.9); p=0.032] (Figure 2). This association was lost when the analysis was 
restricted to stage IV patients and was not observed in patients from C2. No effect from 
baseline autoantibody presence was observed on objective response rates or PFS (Table 4). 
We then tried to gain insight whether the breadth rather than simply examining presence or 
absence of reactivity against NAAs might link to outcomes. We segregated patients with 
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reactivity to exactly one, as opposed to >1 NAA. Unexpectedly, the presence of only 1 NAA 
vs >1 NAA was associated with better PFS [7.3m (95% CI: 5.9-8.6) vs 5.5m (95% CI: 2.8-
8.2); p=0.005] in patients treated with chemo-immunotherapy (Figure 3); a trend was also 
visible in OS [12.3m (95% CI: 4.7-19.9) vs 7.9m (95% CI: 4.9-11); p=0.180]. No such 
association was observed in the chemotherapy only cohort. The detection of multiple vs. 
single reactivities was not associated with ipilimumab-related adverse events in cohort 2 
(colitis, fatigue and rash) nor neurological events.  
We then evaluated the association between NAA against individual antigens and clinical 
outcomes. In patients treated with ipilimumab and chemotherapy, OS was 7.8m (95% CI 2.2-
13.4) when anti-Yo was positive, and 17m (8.7-25.4) when it was negative (p=0.015); PFS 
was 4.3m (95% CI: 2.5-6) when anti-Yo was positive, and 6.9m (95% CI: 6.4-7.5) when anti-
Yo was negative (p=0.081). No other associations were observed between other individual 
NAAs and clinical outcomes. 
In the multivariate analysis in C2 for OS, including poor PS and lack of response to first line 
treatment, having 2 or more vs 1 NAA, remained independently associated with poor outcome 
(HR: 3.4; p-value: 0.033).  
 
Titers of NAA change upon response to treatment 
We quantified the titers of NAAs at each time point (Supplementary Figure 1). Overall in 31 
(68.9%) of the 45 patients with NAAs at baseline, titers decreased after treatment initiation 
(Figure 4). In 22 out of these (48.9%), titers remained lower than baseline at the 3rd time point 
(progression) and in 9 patients (20%) they increased again. In 6 patients (13.4%), titers 
increased after treatment; of these, 2 patients (4.5%) maintained higher titers at progression 
and in 4 patients (8.9%) titers decreased. Autoantibody titers remained unchanged in 2 
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patients (4.5%). Variable patterns of change were observed in the 6 (13.4%) remaining 
patients (example shown in Supplementary Figure 2). 
We then assessed the correlation between the pattern of change of NAAs and response to 
treatment. Of 45 patients with baseline NAA, 42 (93.3%) responded to treatment while 3 
(6.7%) did not. At progression, 25 (59.5%) of previous treatment responders showed an 
ongoing decrease in NAA; all 3 primary non-responder patients showed an increase of titer of 
NAA (p=0.080).  
Next, we evaluated WKHFRUUHODWLRQEHWZHHQVXUYLYDODQGHYROXWLRQRI1$$¶VWLWHUVIn patients 
treated with chemotherapy alone, those whose NAAs increased from baseline to first response 
assessment (N: 6), showed a longer PFS [12 m (95% CI: 11.4-12.6)] compared to those 
showing a decrease in titers (N: 15) [6.9 m (95% CI: 6.1-7.6)] (p: 0.016). This difference was 
not observed in the chemoimmunotherapy cohort. Patients of both cohorts, whose NAA had 
decreased or remained stable at the end of the treatment (third time point) showed an OS of 
18.5m (95% CI: 15.8 ± 21.2) and those whose NAA had increased showed an OS of 12.3m 
(95% CI: 8.1 ± 16.5; p: 0.049). When analyzed separately by treatment, this trend was present 
in the ipilimumab plus chemotherapy [18.5m (95% CI: 9.1-27.8) vs 9.5m (95% CI: 7.0-12.0); 
p: 0.143] and in the chemotherapy alone group [17.2m (95% CI: 12.4-22.1) vs 12.6m (95% 
CI: 8.3-17); p: 0.090]. 
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DISCUSSION: 
SCLC is an aggressive disease with poor outcome. Tumor-associated immunological events 
have been classically described in SCLC in the form of paraneoplastic syndromes, which 
clinically lead to neurological adverse events20. Autoantibodies directed to neuronal antigens 
abnormally expressed in the tumor are detected in patients with PNS and are used as a 
diagnostic tool in this setting21,22. NAAs have been described to be immune effectors of 
neurological dysfunction in the case of membranous antigens (i.e. calcium channel 
antibodies)23. Intracellular antigens may also be subject to a cytotoxic T-cell response, where 
the accompanying antibody production may not be per se pathogenic24±27. Notably, a 
proportion of patients have detectable NAAs in absence of neurological symptoms, although 
generally at lower titers. Dalmau et al. had previously reported a prevalence of around 16% of 
SCLC patients without neurological PNS who have detectable titers of anti-Hu28. Around 1% 
of positivity of anti-HuD was reported in patients diagnosed of PNS 28,29. In a more recent 
study, Gozzard et al. found 9.6% of SCLC patients without neurological PNS with positivity 
for anti-Hu, but when testing also for other NAAs (Sox2, HuD, Gad65, Amphyphisin, Ri, 
Cv2, Ma2 and Yo), 41% patients harbored at least one NAA30. Consistent with these 
observations and in line with previous evidence, 53% of our patients had detectable levels of 
at least one NAA and none had neurological symptoms22,28±33. All but one patient with 
positive detection of anti-HuD, showed lower titers of NAAs in comparison with the patient 
with known anti-HuD related PNS (positive control) (data not shown). 
Consistent with previously reported series22,30, in the current study anti-Sox1 was the most 
prevalent tumor-associated NAA. Unexpectedly, anti-Yo was the second most prevalent NAA; 
although it is usually associated with ovarian and breast cancer, it has also been described in 
lung cancer34,35. Moreover, anti-Gad65, usually linked to autoimmune diabetes36, was 
detected in 3 patients in C1 and in 2 patients in C2. None of these patients had a history of 
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type 1 diabetes in our study.  It could be argued that these detections could be due to technical 
issues with the immune-blot assay. However, this method has been used in previous studies 
and shows good performance LQµVFUHHQLQJ¶VHWWLQJVVXFKDVRXUZRUN37,38. Furthermore, the 
fact of having serial samples for the same patient allowed us to use these as internal controls 
for the positive cases (Supplementary Figure 1).  
The presence of NAAs has been linked to early stages and in turn to better outcome 28,29,32,39. 
The concomitant cytotoxic T cell response27,40±42 might contribute to a degree of tumor 
control, sparing the immune privileged nervous system43,44. In the case of SCLC-associated 
PNS, the diagnosis of the neurological disease often antedates that of the tumor 20,45, 
suggesting that the immune system is able to detect the presence of SCLC before the cancer 
develops metastases39,46. This concept is also supported in other studies where the presence of 
autoantibodies was independently associated with earlier stages 29,47. Accordingly, in our 
series we observed a trend towards an association of NAAs (specifically anti-Sox1) with 
earlier stage.  
When we analyzed the presence of multiple against single NAA reactivities, we observed that 
28% of patients had more than one reactivity. This is consistent with previous literature. In a 
large series of 60,000 subjects with suspicion of PNS, 553 (0.9%) were positive for any NAA 
21; among these, 31% had more than 1 autoantibody. Intriguingly, in our series, patients with 
multiple reactivities had a significantly shorter PFS and OS when treated with the 
combination of chemotherapy and ipilimumab. The presence of coexisting autoantibodies 
reflects a multifaceted response to the different inmunogenic onconeural proteins expressed in 
tumors. The impact of multiple vs. single reactivities has not been reported previously. 
Although small numbers are included in this analysis, if multiple reactivities reflected 
heterogeneity within the tumor and consequently subclonal T cell responses, it has been 
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described that checkpoint inhibitor treatment might be less effective in this scenario48, but this 
is hypothesis generating and requires validation.  
We analyzed the patterns of change in NAA titers in patients treated with chemotherapy vs. 
those treated with chemoimmunotherapy. In most patients the NAA titers decreased after 
initiation of therapy. We note that the addition of ipilimumab to chemotherapy did not appear 
to affect this outcome; this is in contrast with boosting of humoral response to vaccination 
against infectious agents that has previously been reported 49 and also to the effect of 
ipilimumab on tumor-specific T cells that appear to be induced de novo 50. Our data are in line 
with clinical observations in patients with cancer-associated PNS, where in treatment-
responders antibodies can decrease or even normalize 51,52. In a series of 50 cancer patients 
ZLWK3&'DQGDW OHDVWRQH1$$6KDPV¶LOL et al. report resolution of PCD in 9/42 patients 
(21.4%) after successful tumor treatment 53. In 5 neurological responder patients where the 
authors evaluated changes in NAA-titer no consistent pattern was observed. Additional 
immunosupressants for PNS may have also confounded the interpretation in this study. In 
patients with anti-Yo related PNS, antibody titers decreased after surgical removal of the 
tumor without resolution of the neurological symptoms54,55. Overall NAA levels appear to 
decrease following removal of tumor antigen; the observation of worsening PNS with disease 
recurrence32,56 and increase risk of relapse in HPV+ patients whose HPV antibodies persist57 
both support this conclusion. Whether levels of NAA are important clinically or simply 
µE\VWDQGHUV¶RIFHOOXODULPPXQHFRQVHTXHQFHVRIWUHDWPHQWLVXQFHUWDLQ 
An intriguing question arises over the location of the antibody forming cells that drive the 
production of NAA. More widely in oncology, for example in patients with thymoma, 
improvement of paraneoplastic myasthenia is observed after, and is the clinical aim of 
surgical thymectomy. These data point to the production of antibody within the tumor 
microenvironment and there is indeed an emerging literature that identifies B-cells and 
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tertiary lymphatic structures as common constituents in the cancer mass in a wide variety of 
solid tumors 58±61. In contrast, persistence of the neurological paraneoplasia in some cases 
even after radiological complete removal of cancer by treatment both in thymomas and SCLC 
suggests that the antibody forming cells may not be located in the cancer tissue (only) in all 
cases. In line with this, one immunohistochemical study assessing the presence of T and B-
cells in SCLC surgical specimens, demonstrated a small numbers of B-cells infiltrating the 
tissue with 40% of cases with absence of this cell subtype62, although this might change in 
extensive disease. Moreover, we cannot rule out here that the SCLC chemotherapy may have 
also removed B-cells that are producing the NAA irrespective of the effect on tumor load. 
Consistent with the concept that removal of immunogen is linked with a decrease in antibody 
titer, we observed a trend to a longer OS in those patients whose titer of NAA decreased 
progressively after treatment with chemotherapy; this was irrespective of whether ipilimumab 
was administered. 
Intriguingly however, our data also raise the possibility of a quite different immunological 
consequence: subgroup analysis of the small number of patients with increasing titers after 
initiation of chemotherapy identified a longer than median PFS; this raises the question of 
whether enhanced immune response due to intracellular antigen exposure after cytotoxic 
chemotherapy may lead to a better T-cell response and in turn to increased antibody 
production. A dataset in melanoma reported by the Wolchok group is consistent with this 
concept, as the presence or development of antibodies and T-cell responses to NyEso1 
appeared to identify a group of patients, who did well after ipilimumab treatment63. We 
conclude that further detailed studies are needed, which link the humoral responses and 
cellular responses in cancer patients, both after standard treatment and immunotherapy. 
In summary, we were able to confirm the prognostic role of NAA probably related with 
disease control in early stage derived from tumor directed immune response. To our 
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knowledge, we demonstrate for the first time that treatment with ipilimumab combined with 
chemotherapy in SCLC does not induce differential changes in NAA titers and their levels 
appear to mainly reflect the disease burden. The predictive role of NAAs and B cell immune 
response warrants further investigation in SCLC.  
 
PATIENTS AND METHODS 
Study populations 
We retrospectively analyzed the data and serum from 85 SCLC patients from two 
independent cohorts. The first cohort included 47 patients with SCLC treated with first-line 
standard chemotherapy (platinum ± etoposide), recruited within research projects in Hospital 
del Mar, Barcelona, and previously reported 64±66. We included patients with early and locally 
advanced disease as well as stage IV patients, in order to investigate the impact of stage in the 
detection of NAAs.  From this series we had a control population, from age- and sex-matched 
healthy donors (N: 30) to the study population. The second cohort were patients included in 
the ICE trial18, where 38 chemo-naïve stage IV SCLC  patients were treated with ipilimumab 
in combination with carboplatin-etoposide.  Serum samples at baseline and subsequent time 
points (before, during and after treatment) were collected from each patient. Complete clinical 
data and follow up information was available for every patient. 
Sample analysis was approved for the cohort 1 by the local ethics committee and for cohort 2 
within the trial ethics committee. 
 
Sampling 
Serum samples were collected for C1 before treatment initiation (baseline), at first response 
assessment and at progression. For C2, samples were collected at baseline, at 3 and 6 months 
when feasible. All patients in C1 had 3 serial serum samples (baseline, first response 
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assessment and progression timepoints). Out of the 38 patients in C2, 20 had 2, 11 had 3, and 
6 had 4 serial timepoints (all included baseline). One patient in C2 had no available serum 
samples. Serum from 3 healthy volunteers was used as negative controls and serum from a 
SCLC patient with a known anti-HuD associated PNS as a positive control. 
Whole blood samples were collected by standard venipuncture techniques using serum 
separator tubes. Samples were allowed to clot for 30 minutes at room temperature before 
centrifugation for 10 minutes at 1000g at 4ºC. Following centrifugation, the supernatant 
(serum) was immediately removed and assayed immediately or aliquoted and stored frozen at 
-80ºC until further use. 
 
Assessment of autoantibodies 
A commercial immunoblotting assay (Ravo PNS-Blot, Ravo Diagnostika) consisting of a 
membrane strip coated with the recombinant intracellular neuronal antigens Gad65, Sox1, 
Ma1, Ma2, Amphiphysin, CRMP5, Ri, Yo and HuD was used. Patient and control sera were 
diluted 1:200 as established in the current version of the instructions for use (01/2017) and 
SURFHVVHGIROORZLQJPDQXIDFWXUHU¶Vprotocol.  
Incubated line blots were scanned and processed for quantification with ImageJ 1.51h (NIH). 
A distinctive band corresponding to the actual position of the antigen in the line blot was 
considered as a positive signal. Background was subtracted from band intensity. This value 
was normalized with the positive control and the percentage of variation between each time-
point was calculated. A percentage of variation of more than 5% was considered as change 
(increase/decrease) of titer of NAA. Prism 6.0 (GraphPad) was used for plot construction. 
 
Statistical analysis 
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Statistical analysis was carried out using SPSS 22.0 (SPSS Inc, Chicago, IL, USA) and 
Stata/MP 14 (StataCorp LLC, Texas, USA) together with the Statistical Assessment Service 
from IMIM (Hospital del Mar). To analyze associations between categorical variables we 
used the Chi-VTXDUHWHVWRUWKH)LVKHU¶VH[DFWWHVWDVDSSURSULDWH Overall survival was plotted 
by Kaplan±Meier method and curves were compared by the log-rank test. Multivariate 
analysis was performed with the Cox regression method. All tests were conducted at the two-
sided 0.05 level of significance.  
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Figure legends: 
 
Figure 1. Neuronal autoantibodies prevalence in patients with SCLC. On the left, 
percentage and absolute numbers of neuronal autoantibody detected at baseline in each cohort. 
,Q WKH FHQWHU %HQQ¶V GLDJUDPV LOOXVWUDWLQJ WKH GLIIHUHQW 1$$ PXOWL UHDFWLYLWLHV LQ SDWLHQWs 
from both cohorts. On the right we show the combination of NAA with 2, 3 or 4 reactivities. 
1XPEHUVDWWKHLQWHUVHFWLRQRI%HQQ¶VGLDJUDPVDUHQXPEHURISDWLHQWVZLWKWKDWFRPELQDWLRQ.  
 
Figure 2. Overall survival in patients treated with chemotherapy alone (n = 47) with or 
without any baseline NAA.  
 
Figure 3. Progression free survival in patients treated with ipilimumab plus chemotherapy 
with presence of 1 NAA vs 2 or more (n=20). 
 
Figure 4. Changes in autoantibody titers at different time-points in both cohorts. A: 
Patients treated with chemotherapy, whose NAA titers decreased after treatment was started. 
B: Patients treated with chemotherapy and ipilimumab, whose NAA titers decreased after 
treatment was started. C: Patients treated with chemotherapy, whose NAA titers increased 
after treatment was started. D: Patients treated with chemotherapy and ipilimumab, whose 
NAA titers increased after treatment was started, 
 
Supplementary Figure 1. Example of quantification of autoantibodies in consecutives 
time-points. By means of image analysis (ImageJ 1.51h), we quantified the titers of NAA at 
each time point for every patient as the following examples. On the left side of each plot, a 
section of an immunoblot assay showing the reactivity against a specific autoantibody in 
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different time-points of a given patient. On the right, plot showing the variation of intensity of 
the band normalized to the positive control. 
 
Supplementary Figure 2. Plot showing an example of one patient (out of 6) with different 
patterns of change of different NAAs.  
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Tables: 
 
Table 13DWLHQWV¶FKDUDFWHULVWLFV 
 
 
 Cohort 1 
Chemotherapy 
N = 47 
Cohort 2 
Chemotherapy + Ipilimumab 
N = 38 
Gender 
Female 
Male 
 
12 (25.5%) 
35 (74.5%) 
 
13 (34.2%) 
25 (65.8%) 
Age 
Mean 
Range 
 
62.6 
(45 ± 86) 
 
62.5 
(44 ± 84) 
PS 
0 
1 
2 
NA 
 
26 (55,3%) 
14 (29,8%) 
7 (14,9%) 
0 
 
11 (28.9%) 
21 (55.3%) 
0 
6 (15.8%) 
Stage 
I-III 
IV 
 
12 (25,5%) 
35 (74,5%) 
 
0 
38 (100%) 
 
PS: performance status; NA: not available 
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Table 2. Univariate analysis for overall survival including both cohorts (Log-Rank test) 
  95% Confidence interval  
Clinical variables OS (months) Lower Upper p-value 
Gender Male 12.1 7.7 16.5 0.960 
 Female 
 
15.4 11.4 19.3 
Age 
 
< 60 
60y 
 
15.4 
12.2 
10.3 
9.5 
20.4 
15.7 
0.651 
PS 0 15.4 11.7 19.1 0.019 
 1 or 2 
 
9.2 6.6 11.8 
Stage I-III 23.7 11.9 35.6 0.003 
 IV 
 
12.1 8.9 15.3 
Response 
to 1st line 
treatment 
No 6.2 5.4 7.1 < 0.001 
Yes 
 
15.1 12 18.2 
     
 
PS: Performance status; OS: Overall survival; y: years 
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Table 3. Neuronal autoantibody detection at baseline 
 
 Cohort 1 
Chemotherapy 
N = 47 
Cohort 2 
Chemotherapy + Ipilimumab 
N = 38 
Anti-Sox1 
Positive 
Negative 
NA 
 
18 (38.3%) 
29 (61.7%) 
0 
 
13 (34.2%) 
24 (63.2%) 
1 (2.6%) 
Anti-Yo 
Positive 
Negative 
NA 
 
8 (17%) 
39 (83%) 
0 
 
3 (7.9%) 
34 (89.5%) 
1 (2.6%) 
Anti-HuD 
Positive 
Negative 
NA 
 
4 (8.5%) 
43 (91.5%) 
0 
 
4 (10.5%) 
33 (86.8%) 
1 (2.6%) 
Anti-Gad65 
Positive 
Negative 
NA 
 
3 (6.4%) 
44 (93.6%) 
0 
 
2 (5.3%) 
35 (92.1%) 
1 (2.6%) 
Anti-Ri 
Positive 
Negative 
NA 
 
2 (4.3%) 
45 (95.7%) 
0 
 
0 
37 (100%) 
1 (2.6%) 
Anti-CV2 
Positive 
Negative 
NA 
 
0 
47 (100%) 
0 
 
1 (2.6%) 
36 (94.7%) 
1 (2.6%) 
Anti-Amphiphysin 
Positive 
Negative 
NA 
 
0 
47 (100%) 
0 
 
1 (2.6%) 
36 (94.7%) 
1 (2.6%) 
Anti-Ma1 
Positive 
Negative 
NA 
 
0 
47 (100%) 
0 
 
0 
37 (100%) 
1 (2.6%) 
Anti-Ma2 
Positive 
Negative 
NA 
 
0 
47 (100%) 
0 
 
0 
37 (100%) 
1 (2.6%) 
NA: not available  
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Table 4. Objective response rate, progression free survival and overall survival in patients 
with at least 1 baseline positive NAA vs those with no detectable NAAs 
 
 ORR PFS OS 
Cohort 1    
NAAs+ 
NAAs- 
96% 
91% 
7.4m (6.2-8.6) 
6.2m (5.5-7) 
15.1m (10.2-20) 
11.7m (7.5-15.9) 
p-value 0.451 0.279 0.032 
Cohort 2    
NAAs+ 
NAAs- 
90% 
93% 
6.9m (6.6-7.2) 
6.9m (2.7-11.1) 
12.3m (5.3-19.3) 
17m (0-36.1) 
p-value 0.635 0.762 0.796 
 
ORR: objective response rate; PFS: progression free survival; OS: overall survival; NAAs: 
neuronal autoantibodies; +: positive; -: negative 
  
 35 
Supplementary Table 1. Reactivities to different autoantibodies (at any timepoint) 
 
 Chemotherapy 
N = 47 
Chemotherapy+ 
Ipilimumab 
N = 38 
No NAA 22 (46.8%) 
 
17 (44.7%) 
1 NAA 17 (36.2%) 
 
15 (39.5%) 
2 or more NAA 
 
8 (17%) 5 (13.2%) 
Anti-Sox1 + anti-Yo 2 (4.3%) 1 (2.6%) 
Anti-Sox1 + anti-HuD 2 (4.3%) 1 (2.6%) 
Anti-Sox1 + anti-Gad65 1 (2.1%)  
Anti-Sox1 + anti-amphiphysin + 
anti-HuD + anti-Yo 
1 (2.1%) 0 
Anti-Sox1 + anti-Gad65 + anti-
HuD 
1 (2.1%) 0 
Anti-Yo + anti-Gad65 0 2 (5.3%) 
Anti-Yo + anti-Gad65 + anti-Ri 1 (2.1%) 0 
Anti-HuD + anti-CV2 0 1 (2.6%) 
NA 0 1 (2.6%) 
 
NAA: neuronal auto-antibody; NA: not available 
 






